Roche: FDA approves Tecentriq Hybreza

(CercleFinance.com) - Roche announced that the US FDA has approved Tecentriq Hybreza TM (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L) inhibitor for subcutaneous (SC) injection, under the skin, for patients in the US.


Tecentriq Hybreza can be injected subcutaneously in around 7 minutes, compared with 30 to 60 minutes for the standard intravenous (IV) infusion of Tecentriq (atezolizumab).

It will be available for all Tecentriq IV indications approved for adults in the US, including certain types of lung, liver, skin and soft tissue cancer.

By enabling subcutaneous administration of cancer immunotherapy, Tecentriq Hybreza now offers patients with multiple cancer types and their physicians greater flexibility and choice in treatment delivery, said Roche's Medical Director and Head of Global Product Development.


Copyright (c) 2024 CercleFinance.com. All rights reserved.